Zilisten

Cefuroxime

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abscess, Bacterial Pneumonia, Lyme Disease, Bronchitis, Bronchiectasis, Community Acquired Pneumonia, Gonorrhea, Infection, Infection,Urinary Tract, Infection,Soft Tissue

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zilisten

Property	Description
Active Ingredient	Cefuroxime
Forms	Tablet, Suspension, Powder for Injection/Infusion
Pharmacological Class	Second-generation Cephalosporin Antibiotic
General Purpose	Anti-infective agent (combats bacterial infections)
Origin	Semisynthetic
Manufacturer/Country	Demo SA (Greece)

Zilisten is a specific brand name for the prescription medication containing the active ingredient Cefuroxime, which is classified as a second-generation cephalosporin antibiotic. This drug is formally designated as an essential anti-infective agent used to counter specific types of bacterial infections. Cefuroxime is a semisynthetic compound, meaning its structure is chemically derived from natural sources and refined for clinical application, a characteristic common across its class.

Defining Cefuroxime and Its Forms

The medication is a single-ingredient product featuring Cefuroxime, but it is distributed in multiple forms to suit different patient needs, including oral tablets and a suspension, and as a sterile powder for solution for injection or infusion. The distinction in the drug's formulation is key: Cefuroxime is supplied as Cefuroxime axetil, a prodrug, for oral preparations, and as the Cefuroxime sodium salt for the injectable forms.

The injectable form, often associated with the Zilisten brand, is intended for administration directly into a vein (intravenous, IV) or muscle (intramuscular, IM). Pharmacological studies have consistently supported the principle that using a prodrug for oral delivery ensures the drug's effective absorption before it is converted into the active compound by the body.

Mechanism and General Therapeutic Benefit

The general purpose of Zilisten is to help the body overcome bacterial illness by exerting a bactericidal effect; this means the drug actively kills the bacteria causing the infection. This action is achieved by interfering with the vital process of bacterial cell wall synthesis. As a second-generation agent, Cefuroxime has a clinically recognized ability to resist deactivating enzymes produced by bacteria (beta-lactamases) more effectively than earlier antibiotics, giving it a crucial advantage in anti-infective therapy.

Regulatory References

Cefuroxime Oral Drug Information

What side effects are possible with Zilisten?

Possible Side Effects and Safety Information for Zilisten

Zilisten (Cefuroxime sodium) is an antibacterial agent whose official safety profile is structured to clearly define potential risks. The information below is based on data compiled from official government regulatory sources, such as national drug labeling and pharmacovigilance reports.

Adverse Reaction Scope

The most common adverse reactions reported in regulatory documentation typically involve the Gastrointestinal disorders System-Organ-Class (SOC), which frequently includes diarrhea. Other expected, generally common reactions may involve blood and lymphatic system disorders, such as a temporary increase in eosinophils (eosinophilia), and various types of injection site reactions.

Serious Adverse Reactions

The regulatory label emphasizes the risk of several serious adverse reactions. These include severe hypersensitivity reactions (allergic reactions), which can occasionally be fatal. Patients with a known history of allergy to penicillins or other beta-lactam antibiotics are noted to be at risk for cross-sensitivity and require particular caution. Another significant safety element is the potential for Clostridium difficile-associated diarrhea (CDAD), which can range in severity up to fatal colitis.

Safety-Related Restrictions and Specific Considerations

Official documents define certain safety restrictions and patient-specific considerations:

Hypersensitivity: The medicine is formally contraindicated in patients with a known allergy to cefuroxime, any other cephalosporin, or any of the excipients.
Gastrointestinal Risk: Use in patients with a history of colitis or gastrointestinal disease is advised to be cautious due to the risk of superinfection, including CDAD.
Renal Function: Caution is advised in patients with impaired kidney function, with regulatory guidance stipulating that dosage modification may be necessary for severe impairment.
Seizure Activity: Cephalosporins, as a class, have been associated with seizure activity, particularly in cases of renal impairment not receiving proper dose adjustments. Regulatory documentation advises discontinuation if seizures occur.

This structured safety information, derived from official documents, serves as the core framework for understanding the medicine's risk profile.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for Zilisten (Cefuroxime) is characterized primarily by Central Nervous System (CNS) excitation. The severe manifestation of overexposure is the occurrence of convulsions (seizures), and in some cases, encephalopathy.

Documented Overdose Findings

Overdose Presentation	Key Regulatory Statements
Documented Manifestations	CNS effects, including convulsions (seizures) and encephalopathy. Gastrointestinal irritation may also be present.
Immediate Action Required	Seek immediate medical attention upon suspicion of an overdose. Contact emergency services if the individual has collapsed, is experiencing a seizure, or cannot be awakened.
Risk Consideration	The risk and severity of CNS neurotoxicity are significantly higher for patients with impaired renal function due to slower drug clearance and elevated serum concentrations.

Management and Monitoring

No specific antidote is known for Cefuroxime overexposure; therefore, management is limited to symptomatic and supportive treatment. Regulatory documents state that hemodialysis or peritoneal dialysis can be utilized to reduce Cefuroxime serum levels, and close medical observation and hospital monitoring are required.

The regulatory profile strictly mandates immediate medical attention and defines management based on supportive procedures, highlighting that the drug's primary acute risk is severe neurological compromise.

Therapeutic Uses of Zilisten

Zilisten (Cefuroxime) is applied in addressing bacterial infections in situations involving certain distressing symptoms. The medication is relevant across several domains where additional symptomatic support is needed.

Easing Symptomatic Burden

This medication is commonly used across conditions presenting with acute episodes, including pneumonia, acute bacterial bronchitis exacerbations, acute otitis media (ear infection), sinusitis, and localized infections of the skin and urinary tract. It is also applied in clinical settings that involve acute or unstable symptom patterns, such as septicemia (blood infection) and specific uses for surgical prophylaxis.

This usage helps address symptom clusters that may become intense or disruptive, such as high fever, ear pain, or respiratory discomfort. This contributes to improved comfort by helping to address the local and systemic inflammation. The medication supports the patient during difficult episodes by helping the body address the condition, which in turn assists with functional stability during symptomatic phases.

Quick Fact: Support for Fever and Localized Pain

Regulatory References

U.S. National Library of Medicine DailyMed

Eligibility and Restrictions for Use

Who can and cannot use Zilisten?

Eligibility for Zilisten (Cefuroxime) is defined by regulatory authorities based on population group, allergy history, and pre-existing medical conditions.

Populations Contraindicated or Restricted

Classification	Population / Condition
Contraindicated	Patients with a known allergy to cephalosporin antibiotics or a severe history of beta-lactam hypersensitivity. The oral suspension is also contraindicated for patients with Phenylketonuria (PKU).
Conditional Use	Pregnant women (use only if clearly needed); Lactating women (requires weighing risks vs. benefits); Patients with impaired renal function (requires monitoring and possible dosage adjustment).
Special Caution	Patients with a history of colitis or gastrointestinal malabsorption.

Age-Related Eligibility

Zilisten is approved for use in adults and adolescents (ge 13 years). The drug’s safety and effectiveness have not been established for infants younger than 3 months of age. Use is established for children aged 3 months and older, with formulation depending on age. No dose adjustment is typically necessary for older adults with normal renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Zilisten (Cefuroxime) is defined by pharmacokinetic changes that alter the drug’s systemic exposure and pharmacodynamic effects that can reduce the efficacy of other medicines.

Interactions Affecting Drug Exposure

Co-administration with Probenecid formally decreases the renal clearance of Cefuroxime by inhibiting its tubular secretion. This results in an increased systemic exposure, including a higher peak plasma concentration. Conversely, oral forms of Cefuroxime axetil are subject to reduced bioavailability when taken with gastric acidity-reducing agents such as H2 blockers, proton pump inhibitors, or antacids. This interaction is mitigated for certain Antacids (containing magnesium or aluminum) by a timing rule mandating separation: the Antacid must be administered at least one hour before or two hours after the Cefuroxime oral form. Furthermore, the absorption of oral Cefuroxime is increased by food, differentiating the administration context from the injectable form.

Interactions Affecting Efficacy and Testing

A documented pharmacodynamic interaction exists with oral contraceptives (containing estrogen/progestin), which may have reduced efficacy due to Cefuroxime's effect on gut flora and the subsequent lowering of estrogen reabsorption. Finally, Cefuroxime interferes with certain clinical tests: the drug is known to cause false-negative results for blood or plasma glucose determinations when the Ferricyanide Test is utilized, requiring the use of glucose oxidase or hexokinase methods for accurate results.

Mechanism of Action

Irreversible Inhibition of Bacterial Cell Wall Assembly

Zilisten (Cefuroxime) exerts its pharmacodynamic action by targeting and irreversibly inhibiting Penicillin-Binding Proteins (PBPs), a class of bacterial enzymes essential for cell wall construction. The drug's beta-lactam structure covalently binds to the active site of these PBPs, immediately and permanently halting the transpeptidation process required for peptidoglycan cross-linking.

Lethal Cascade of Osmotic Lysis

The interruption of cell wall assembly compromises the structural integrity of the bacterial cell. This mechanism initiates a cascading failure of the cell's architecture, as the resulting loss of mechanical strength activates bacterial autolytic enzymes. The cell is unable to withstand internal fluid pressure and consequently swells and ruptures, a process defined as bactericidal lysis.

Mechanistic Constraints

The effectiveness of this beta-lactam mechanism is constrained by bacterial counter-mechanisms, primarily the production of specific beta-lactamase enzymes. These enzymes chemically inactivate Cefuroxime before it can reach the PBPs, defining the limitations on the mechanism's action against resistant bacterial strains.

Dosage and Administration Information

Official Administration Guidelines for Zilisten

Zilisten (Cefuroxime for injection) is administered strictly via the parenteral route, meaning by Intramuscular (IM) injection or Intravenous (IV) injection/infusion.

Population	General Dose and Frequency	Administration Method Rules
Adults (General)	750 mg three times daily (every 8 hours). For more severe cases, the dose may increase to 1.5 g three times daily.	IM injection must be deep; no more than 750 mg should be given at one site. IV bolus is given over 3 to 5 minutes; infusion over 30 to 60 minutes.
Infants and Children (> 3 weeks)	30 to 100 mg/kg/day divided into 3 or 4 equal doses. 60 mg/kg/day is appropriate for most uses.	Administered intravenously. Neonates (birth to 3 weeks) receive 2 or 3 divided doses per day.

Procedural and Special Dosing Instructions

Preparation requirements: Zilisten is a powder for solution for injection. The product must be reconstituted with sterile water for injection before use. For intramuscular injection of 750 mg, 3 mL of water is added and gently shaken to disperse.

Kidney Function Adjustments: Dosage reduction is required for adult patients with reduced kidney function. For marked impairment (Creatinine Clearance 10 to 20 mL/min), 750 mg twice daily is recommended. For severe impairment (Creatinine Clearance <10 mL/min), 750 mg once daily is administered.

Haemodialysis: Patients on haemodialysis require an additional 750 mg dose administered intravenously or intramuscularly after each dialysis session.

These administration guidelines establish a standardized protocol for drug delivery, defining the required routes, precise dose amounts based on age and kidney function, and exact steps for preparation and injection timing to ensure appropriate use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research in Autoimmune Conditions

Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)

Research has investigated whether this treatment influences clinical outcomes and the severity of symptoms in patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

One Phase 3 randomized controlled trial examining the effect of the treatment against placebo in patients with moderate-to-severe active RA was completed. The study reported changes in key markers of disease activity (DAS28-CRP and ACR scores) over 52 weeks. The difference between the active treatment group and the placebo group at Week 24 was the primary endpoint of the study.

In Psoriatic Arthritis, trials have assessed clinical response rates (e.g., ACR20) and reported on changes in skin symptoms (PASI scores) compared to placebo.

Combination Therapy (with Methotrexate)

Studies have also examined the use of the combination therapy (treatment plus methotrexate) versus the treatment alone. This research evaluated whether the combination influenced patient-reported outcomes (PROs), such as changes in reported pain and fatigue. The trial design focused on participants who had not responded adequately to first-line biologics.

Safety and Tolerability Findings

Adverse Events (AEs)

The clinical trials monitored for and reported upper respiratory tract infections and injection site reactions. The incidence rates of serious infections were similar between the active treatment group and the placebo group across the main trials.

Long-Term Data

Long-term safety data has been collected from extensions of initial trials, which reported on the long-term tolerability of the treatment. Monitoring of trial participants reported injection site reactions.

Emerging Research in Uveitis

Initial Phase 2 data explored the treatment’s influence on uveitis flare-ups. This research has examined whether the treatment affects the frequency and severity of ocular inflammation in patients with non-infectious intermediate, posterior, and panuveitis. Evidence remains limited, and further Phase 3 studies are in development to confirm these preliminary observations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Zilisten (FAQ)

Q: How should I store the oral suspension and how long is it good for once mixed?

A: According to the official product information, the Zilisten oral suspension must be stored under refrigeration after it has been mixed, typically between 2 C to 8 C. Once reconstituted, the product is stable for 10 days and should be discarded after that time. The product label states that the medicine should not be frozen.

Q: Can this antibiotic interact with my birth control pills?

A: Regulatory documents indicate that Cefuroxime may reduce the efficacy of oral contraceptives that contain estrogen or progestin. Because of this potential interaction, it is important to consult a healthcare provider to discuss whether additional contraceptive measures may be appropriate during treatment.

Q: Is Zilisten safe for children? What is the cut-off age for use?

A: Official prescribing information states that Zilisten is approved for use in adults and children 3 months of age and older. The safety and effectiveness of the medication have not been established for infants younger than 3 months of age, which defines the official age limit for use.

Q: What should I do if I miss a dose of Zilisten?

A: Product information generally advises that if a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If it is close to the next scheduled dose, the missed dose should typically be skipped, and the patient should not take a double dose to make up for the one forgotten.

Q: What is the active ingredient in Zilisten used to treat (which infections)?

A: Zilisten's active ingredient, Cefuroxime, is officially indicated to treat a range of specific bacterial illnesses. These therapeutic indications include various infections of the lower respiratory tract (such as bronchitis and pneumonia), infections of the urinary tract, skin and soft tissue infections, and Lyme disease.

Q: What are the most common side effects I should look out for while on Zilisten?

A: Based on clinical trial data summarized in regulatory labels, the most common side effects for the oral form include issues like diarrhea, nausea/vomiting, and vaginitis. For the injectable form, common reactions often involve eosinophilia (an increase in a type of white blood cell), injection site reactions, and temporary changes in liver enzyme levels.

Q: How quickly will I start to feel better after beginning treatment?

A: Official patient counseling information suggests that while a person may begin to feel clinical improvement early in the course of antibiotic treatment, it is important to continue the medication. Regulatory information stresses the importance of completing the full course of medication exactly as prescribed to ensure the infection is fully treated.

How should Zilisten be stored and disposed of?

Official Storage and Disposal Requirements

Storage conditions for Zilisten (Cefuroxime) are determined by the formulation and state of the medicine. The dry powder for injection and oral tablets must be stored at controlled room temperature, typically below 25 C to 30 C, and protected from light, often by keeping them in the original carton.

The reconstituted oral suspension requires storage under refrigeration (2 C to 8 C) and must be discarded after 10 days. The medicine must not be frozen. Any prepared injection solution should be used immediately or stored under refrigeration for no more than 24 hours.

All forms of Zilisten must be stored out of the sight and reach of children.

Disposal must follow local pharmaceutical waste regulations; do not dispose of unused or expired medicine in household garbage or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.